Principal investigator

Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Tuesday, September 14, 2021 - 4:00pm

Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.

Key Points: 
  • Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
  • Immunicoms ongoing clinical trials are in the most difficult to treat, late-stage cancer patients.
  • Immunicoms novel Immunopheresis therapy uses its proprietary subtractive LW-02 column to selectively remove immune-suppressive cytokines produced by cancer tumors.
  • Standard cancer treatments are surgery, radiation or those that typically require the infusion of drugs, antibodies or proteins into the patient.

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Monday, September 13, 2021 - 2:43pm

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
    Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,
    We are pleased to say that 2021 has been a busy and transformative year for the Company.
  • During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company.
  • We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.

Navigation Sciences™ Awarded $400,000 NCI SBIR/STTR Program Grant to Support Development of NaviSci™ Intelligent Surgical System Use in Removal of Early-Stage Lung Tumors

Thursday, September 9, 2021 - 2:00pm

The NaviSci System, currently undergoing a clinical feasibility study, is designed to accurately determine surgical margins in real-time and enable tumor removal through a targeted, minimally invasive surgery.

Key Points: 
  • The NaviSci System, currently undergoing a clinical feasibility study, is designed to accurately determine surgical margins in real-time and enable tumor removal through a targeted, minimally invasive surgery.
  • Principal Investigator on the grant, Associate Professor at Harvard Medical School, and a Navigation Sciences co-founder.
  • The initial system in clinical development relies on visual localization or C-arm CT imaging to guide placement of the marker.
  • Navigation Sciences is a clinical-stage company developing the NaviSci System for the tissue conserving removal of lung cancer and other soft tissue tumors.

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Wednesday, September 8, 2021 - 3:26am

EnGeneIC has commenced a Phase I clinical trial dosing healthy adults at St Vincents Hospital, Melbourne using its patented nanocell technology platform (EDV; EnGeneIC Dream Vector).

Key Points: 
  • EnGeneIC has commenced a Phase I clinical trial dosing healthy adults at St Vincents Hospital, Melbourne using its patented nanocell technology platform (EDV; EnGeneIC Dream Vector).
  • A seminal publication on the preclinical studies is in preparation for a major scientific journal.
  • EnGeneIC is now in Phase 2a clinical trials in patients with intractable cancers, including patients with metastatic pancreatic cancer.
  • EnGeneIC was also featured in theDecember 2019issue ofInsightsCaremagazine as The Top 10 Nanotech Companies to Watch.

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

Wednesday, September 8, 2021 - 1:05pm

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m.

Key Points: 
  • SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m.
  • In addition to presentations by Metacrines senior management team, the R&D Day will feature discussions from renowned key opinion leaders (KOLs) including:
    Juan Pablo Frias, M.D.
  • Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-thalassemia

Wednesday, September 8, 2021 - 11:00am

The NMPA approved clinical trial of ET-01 is a multicenter, open-label study designed to assess its safety and efficacy in transfusion dependent -thalassemia patients.

Key Points: 
  • The NMPA approved clinical trial of ET-01 is a multicenter, open-label study designed to assess its safety and efficacy in transfusion dependent -thalassemia patients.
  • The other participating clinical sites are Shenzhen Childrens Hospital and Guangzhou Women and Childrens Medical Center.
  • The site activation and first patient enrollment mark a significant step towards bringing the potential one-time cure for patients with transfusion dependent thalassemia.
  • It is an investigational, autologous, ex vivo gene-edited hematopoietic stem cell therapy for transfusion dependent -thalassemia patients.

Anova Launches Global Patient Registry Study to Better Understand Clinical Trials and Patient Outcomes

Wednesday, August 25, 2021 - 5:00pm

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS technology platform, has launched a global patient registry study for 100,000 patients with complex and/or rare disease.

Key Points: 
  • Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS technology platform, has launched a global patient registry study for 100,000 patients with complex and/or rare disease.
  • The Registry Study will also be used to study the design and conduct of clinical trials and observational studies.
  • This is the first study into the ability of patients to access clinical trials or treatments through compassionate use.
  • The Registry will expedite identification and recruitment of participants for clinical trials of promising therapeutics and observational studies.

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis

Wednesday, August 25, 2021 - 6:00am

Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.

Key Points: 
  • Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.
  • gMG is a severe, chronic and debilitating disease that can be unpredictable and greatly impact a persons quality of life.
  • Myasthenia gravis (MG) is a rare and chronic autoimmune disease, often causing debilitating and potentially life-threatening muscle weakness.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Privo Technologies, Inc. Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant

Monday, August 23, 2021 - 7:00pm

"We are very grateful to the NIDCR and NIH for their continued support for the late-stage development and commercialization of PRV111," said Manijeh Goldberg, Ph.D., CEO of Privo Technologies, Inc. and Principal Investigator on the grants.

Key Points: 
  • "We are very grateful to the NIDCR and NIH for their continued support for the late-stage development and commercialization of PRV111," said Manijeh Goldberg, Ph.D., CEO of Privo Technologies, Inc. and Principal Investigator on the grants.
  • "Here at Privo, we seek to transform the standard of care for patients suffering from mucosal cancers that typically require disfiguring and disabling surgeries.
  • This grant will be instrumental in developing PRV111 from a clinical to a commercial stage asset."
  • NIDCR prioritizes scientific opportunities based on the potential impact to improve health, the readiness of the scientific community to accomplish these opportunities, and their alignment with the Institution's mission.

Mainstay Medical Announces Participation at the American Association of Neurological Surgeons (AANS) Annual Meeting

Monday, August 23, 2021 - 1:00pm

Mainstay Medical Holdings plc today announced its participation in the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be hosted virtually on August 21-25, 2021.

Key Points: 
  • Mainstay Medical Holdings plc today announced its participation in the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be hosted virtually on August 21-25, 2021.
  • Mainstay Medicals participation will focus on ReActiv8, its implantable Restorative Neurostimulation system to treat intractable chronic low back pain.
  • We are excited to introduce ReActiv8 to the AANS membership, said Jason Hannon, CEO of Mainstay Medical.
  • Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.